Metal complexes as artificial proteases: toward catalytic drugs.
Catalytic cleavage of the backbone of a protein related to a disease may cure the disease. Owing to the catalytic nature of the protein inactivation, the drug dosage and the side effects can be reduced with the catalytic drugs. Catalytic drugs can be designed even for proteins lacking active sites. Effective artificial proteases have been designed for proteins or oligomers of oligopeptides. The Co(III) complex of cyclen has been used as the catalytic center for peptide hydrolysis. Binding sites of the catalysts that recognize the targets have been searched by using various kinds of chemical libraries. Some of the artificial metalloproteases reported till date offer a new therapeutic option for amyloidoses (e.g. Alzheimer's disease, type 2 diabetes mellitus, Parkinson's disease, mad cow's disease, etc.).
Suh
Junghun
J
Department of Chemistry, Seoul National University, Seoul 151-747, Republic of Korea. jhsuh@snu.ac.kr
Chei
Woo Suk
WS
D002384:Catalysis; D006868:Hydrolysis; D045726:Metalloproteases / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D008670:Metals / Q000378:metabolism*; D009842:Oligopeptides / Q000378:metabolism; D011506:Proteins / Q000378:metabolism
D008670:Metals; D009842:Oligopeptides; D011506:Proteins; D045726:Metalloproteases